The Q32 Bio Inc. (QTTB) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K that highlight material events. Q32 Bio’s filings reflect its status as a Nasdaq-listed clinical stage biotechnology company focused on alopecia areata and other autoimmune and inflammatory diseases.
Recent Form 8-K filings referenced by Q32 Bio include reports furnished under Item 2.02 for quarterly financial results and corporate updates, and under Item 8.01 for other events such as clinical trial milestones. For example, the company has filed 8-Ks in connection with press releases announcing financial results for specific quarters, as well as an 8-K describing the completion of enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata. Another 8-K details leadership changes under Item 5.02, including the resignation of a Chief Medical Officer and the appointment of an interim Chief Medical Officer.
Q32 Bio’s 8-K filings also confirm that its common stock, with a par value of $0.0001 per share, is registered pursuant to Section 12(b) of the Exchange Act and trades on Nasdaq under the symbol QTTB. The filings typically attach press releases as exhibits, which are incorporated by reference where specified, and clarify whether the information is being furnished rather than filed for purposes of Section 18 of the Exchange Act.
On Stock Titan, these SEC documents are updated as they become available from EDGAR and are paired with AI-powered summaries that explain the key points in accessible language. Users can quickly see which filings relate to financial results, clinical trial updates, leadership changes, or other corporate events, and can review the underlying forms and exhibits for more detail.
Q32 Bio Inc. reported 36-week topline results from Part B of its SIGNAL-AA Phase 2a trial of bempikibart (ADX-914) in severe and very severe alopecia areata. In the modified intent-to-treat population of 25 patients, the mean Severity of Alopecia Tool (SALT) score was reduced by 35.3%, with a 37.8% reduction in severe patients and 27.4% in very severe patients.
Clinically meaningful responses were observed, with 40.0% of the mITT population and 30.3% of the full ITT population (33 patients) achieving SALT-20 at Week 36. Example cases showed patients reaching SALT-10 or SALT-0 and maintaining or deepening responses during 12–16 weeks off drug and into an open-label extension.
The company stated that bempikibart demonstrated a generally well-tolerated safety profile, with no Grade 3 or higher adverse events and low, mild injection site reaction rates among 33 treated patients. Pharmacokinetic data indicated steady state concentrations were achieved about 10 weeks earlier than in Part A, with negligible anti-drug antibodies. Q32 Bio plans to use the SIGNAL-AA data to engage the FDA on a registration-directed program targeting initiation in the first half of 2027.
Q32 Bio Inc. reported 36-week topline results from Part B of its SIGNAL-AA Phase 2a trial of bempikibart in severe and very severe alopecia areata. In 33 treated patients, the prespecified modified intent-to-treat analysis showed a 35.3% mean reduction in SALT score from baseline, with 40.0% of patients achieving a SALT-20 response at Week 36 in the mITT set and 30.3% in the ITT set of all enrolled patients.
Bempikibart was observed to have a generally well-tolerated safety profile, with no treatment-related serious adverse events or Grade 3 or higher events and mild injection site reactions in 36.3% of patients, corresponding to a 4% incidence across all dose administrations. Pharmacokinetic, pharmacodynamic and anti-drug antibody data were favorable, with the loading regimen achieving steady-state about 10 weeks earlier than in Part A and negligible ADA formation.
The Part A open-label extension in eight patients also supported longer-term tolerability and suggested durable or further hair growth for those maintaining hair at entry, reinforcing the importance of maintenance dosing. The company plans to advance bempikibart into a registration-directed program in the first half of 2027 and recently repaid the remaining approximately $6.8 million outstanding under its loan agreement with Silicon Valley Bank, which has now been terminated.
Q32 Bio Inc. has a large shareholder group led by Boxer Capital Management, LLC, Boxer Holdings, LP, Boxer Holdings GP, LLC, and Aaron Davis collectively reporting beneficial ownership of 3,149,310 shares of common stock as of June 30, 2026. This represents 13.30% of Q32 Bio’s outstanding common stock. The ownership is reported with shared voting and dispositive power over all 3,149,310 shares and no sole voting or dispositive power.
The percentage is calculated based on 23,681,415 shares outstanding, consisting of 16,956,415 shares outstanding as of May 1, 2026 plus 6,725,000 shares issued in a private placement that closed on May 28, 2026.
Q32 Bio Inc. Schedule 13G/A shows that a group of Carlyle-related entities reports shared beneficial ownership of 691,735 shares of Common Stock, representing 4.1% of the class as of June 18, 2026. The filing cites 16,956,415 shares outstanding as disclosed in the issuer's Form 10-Q filed May 5, 2026. The reporting chain traces record ownership to Abingworth Bioventures VII LP with investment/dispositive authority delegated to Abingworth LLP; multiple Carlyle entities disclaim direct beneficial ownership while the cover pages report shared voting and dispositive power.
Q32 Bio Inc. director Isaac Manke exercised stock options to acquire 53,521 shares of Common Stock on June 30, 2026 at an effective exercise price of $2.80 per share. Following the exercise, he directly holds 53,521 common shares and the corresponding option position reported in this filing has been fully exercised.
The exercised option, described as a Stock Option (Right to Buy), had granted rights over 53,521 shares of Common Stock and was fully vested and exercisable. After this transaction, the derivative position shown in the filing has a reported balance of 0 options, indicating a complete exercise of this award with no sale reported in this filing.
Q32 Bio Inc. filed a shelf registration to offer up to $300,000,000 of common stock, preferred stock, debt securities, warrants and units from time to time, in one or more offerings. The prospectus states offerings will be made at prices and on terms determined at or prior to each offering and that specific terms will appear in prospectus supplements.
The prospectus notes the company completed a $55 million securities purchase on May 26, 2026 with related registration rights and discloses 1,025,654 pre-funded warrants exercisable at $0.0001 per share. The filing is a shelf registration (Form S-3) enabling future capital raises under Rule 415.
Q32 Bio Inc. director Kathleen LaPorte received a grant of stock options covering 9,810 shares of common stock at an exercise price of $12.64 per share. These options vest in full on the earlier of June 12, 2027 or the company’s next annual stockholder meeting, subject to her continued service, and represent her entire reported option position in this filing.
Q32 Bio Inc. director Mark T. Iwicki received a grant of stock options covering 9,810 shares of common stock. The options have an exercise price of $12.64 per share and expire on June 11, 2036. They vest in full on the earlier of June 12, 2027 or the company’s next annual stockholder meeting, contingent on his continued service.
Q32 Bio Inc. director Isaac Manke received a grant of stock options covering 9,810 shares of common stock. These options have an exercise price of $12.64 per share and were awarded as compensation, not through an open-market purchase or sale.
The options vest and become exercisable in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders, subject to Manke’s continued board service on that vesting date. Following this grant, he holds 9,810 derivative securities tied to Q32 Bio common stock directly.
Q32 Bio Inc. director Arthur Tzianabos received a grant of stock options representing 9,810 shares of common stock. The options have an exercise price of $12.64 per share and expire on June 11, 2036. Following this grant, he holds 9,810 options directly from this award in this filing.
According to the vesting terms, these options will vest and become exercisable in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders, provided he continues to serve with the company through the applicable vesting date.